Publication Name	World Journal of Gastroenterology
Manuscript ID	2429
Country	China

Received	2013-02-21 09:36
Peer-Review Started	2013-02-21 19:54
To Make the First Decision	2013-03-11 15:07
Return for Revision	2013-03-17 18:43
Revised	2013-03-31 22:34
Second Decision	2013-04-17 10:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-04-17 11:10
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-05-22 09:57
Publish the Manuscript Online	2013-06-04 12:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Manuscript Source	Invited Manuscript
All Author List	Qing-Lei Zeng, Ji-Yuan Zhang, Zheng Zhang, Li-Feng Wang and Fu-Sheng Wang
Funding Agency and Grant Number	Funding Agency Grant Number National Key Basic Research Program of China 2009CB522507 National Key Basic Research Program of China 2012CB519005 Beijing Nova Program of China Z12110702512071
Corresponding Author	Fu-Sheng Wang, MD, PhD, The Institute of Translational Hepatology, Beijing 302 Hospital, Peking University, 100 Xisihuan Middle Road, Beijing 100039, China. fswang302@163.com
Key Words	Sofosbuvir; ABT-450; Hepatitis C virus; Antiviral therapy; Sustained virologic response
Core Tip	We are entering an era in which the development of antiviral agents and successful treatment of chronic hepatitis C is rapidly escalating. In this review, we have summarized the history of anti-hepatitis C virus (HCV) agents from interferon-α (IFN-α) to the latest sofosbuvir- and ABT-450-based therapies. Although a new generation of direct acting anti-HCV agents has largely improved the sustained virologic response rates of patients, many unmet needs and questions remain, such as IFN-free regimens for difficult to treat patients, avoidance of cross-resistance, the role of interleukin-28B status as well as the management of some advanced and co-infected patients.
Publish Date	2013-06-04 12:34
Citation	Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206
URL	http://www.wjgnet.com/1007-9327/full/v19/i21/3199.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i21.3199

Full Article (PDF)	WJG-19-3199.pdf
Manuscript File	2429-Review.docx
Answering Reviewers	2429-Answering reviewers.doc
Copyright License Agreement	2429-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate	2429-Language certificate.pdf
Peer-review Report	2429-Peer review(s).pdf
Scientific Editor Work List	2429-Scientific editor work list.doc